By end of Apr , 2022, Shanghai HeartCare Medical Technology Corporation Limited received approval from the National Medical Products Administration for FlowPlus® Aspiration Catheter, Spiflex® Support Catheter and Laager® LAAO, which marks the 13^th to 15^th product ever launched and marks another milestone towards the target to provide one-stop solution and become the industry leader for stroke therapeutics and prevention, with our full-set pipeline of products for acute ischemic stroke ,neurovascular stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment, and interventional vascular access.